



People. Trust. Results.  
Since 1960

## The New Year Rings-In Change to CMS' "14 Day Rule" for Its Laboratory Date of Service Policy

Prior to 2018, CMS' 14 Day Rule prevented reference and independent laboratories from billing Medicare directly for molecular pathology tests ordered less than 14 days following an outpatient's discharge from the hospital. Instead, the laboratory would seek reimbursement from the hospital and the hospital would bill Medicare.

Although molecular tests were not bundled into hospital payment packages by the Hospital Outpatient Prospective Payment System (OPPS) fee schedule, CMS treated them as such when they were ordered within 14 days of a patient's discharge.

A main factor in the issue is CMS' Date of Service (DOS) policy, which generally requires that the DOS for clinical diagnostic laboratory services is the date the specimen is collected. Medicare has been clear that the DOS may affect payment for a test, especially when the specimen was collected while the patient was being treated in the hospital and is later used for testing after the patient has been discharged.

Besides the obvious administrative challenges this represents for both labs and hospitals, there has been growing clinical concern voiced over potential delays in patient testing, access to test results, and implementation of treatment plans as the 14 day timeframe is accommodated.

In response, the 2018 CMS OPPS Final Rule created an exception to the 14 Day Rule and modified its DOS Policy specifically for hospital outpatients receiving MolDX Tier 1 and Tier 2 molecular tests and advanced diagnostic laboratory tests (ADLT).

Effective January 1, 2018, in the case of the above tests, the DOS must be the date the test was performed instead of the date the specimen was obtained, as long as the following conditions are met.

- The physician orders the test following the date of a hospital outpatient's discharge from the hospital outpatient department
- The specimen was collected from a hospital outpatient during an outpatient encounter
- It would be medically inappropriate to have collected the sample from the hospital outpatient other than during the hospital outpatient encounter
- The results of the test do not guide treatment provided during the hospital outpatient encounter
- The test was reasonable and medically necessary for the treatment of an illness

This revision now enables labs performing specific molecular pathology tests to bill Medicare directly instead of seeking reimbursement from the hospital.

It is important to note the following exceptions to this laboratory DOS change:

1. The exception only applies when the specimen has been obtained from a hospital outpatient, not inpatient
2. The exception does not apply to Gene Sequencing procedures (GSPs), Proprietary Laboratory Analysis tests (PLAs), or Protein-based Molecular Multi-Analyte Assays with Algorithmic Analysis (MAAAs); hospitals will continue billing Medicare for these tests when ordered less than 14 days following a hospital outpatient's discharge.

On the following pages is a comprehensive list of all molecular tests that are exempt from the 14 day DOS rule.



People. Trust. Results.

Since 1960

<b>MoIDX Tier 1 and Tier 2 CPT Codes Subject to Laboratory DOS and 14 Day Rule Changes 2018 OPSS Payment Schedule – Addendum B</b>			
<b>81105</b>	Hpa-1 genotyping	<b>81270</b>	Jak2 gene
<b>81106</b>	Hpa-2 genotyping	<b>81272</b>	Kit gene targeted seq analys
<b>81107</b>	Hpa-3 genotyping	<b>81273</b>	Kit gene analys d816 variant
<b>81108</b>	Hpa-4 genotyping	<b>81275</b>	Kras gene variants exon 2
<b>81109</b>	Hpa-5 genotyping	<b>81276</b>	Kras gene addl variants
<b>81110</b>	Hpa-6 genotyping	<b>81283</b>	Ifnl3 gene
<b>81111</b>	Hpa-9 genotyping	<b>81287</b>	Mgmt gene methylation anal
<b>81112</b>	Hpa-15 genotyping	<b>81288</b>	Mlh1 gene
<b>81120</b>	Idh1 common variants	<b>81290</b>	Mcoln1 gene
<b>81121</b>	Idh2 common variants	<b>81291</b>	Mthfr gene
<b>81161</b>	Dmd dup/delet analysis	<b>81292</b>	Mlh1 gene full seq
<b>81162</b>	Brca1&2 seq & full dup/del	<b>81293</b>	Mlh1 gene known variants
<b>81170</b>	Abl1 gene	<b>81294</b>	Mlh1 gene dup/delete variant
<b>81175</b>	Asxl1 full gene sequence	<b>81295</b>	Msh2 gene full seq
<b>81176</b>	Asxl1 gene target seq alys	<b>81296</b>	Msh2 gene known variants
<b>81200</b>	Aspa gene	<b>81297</b>	Msh2 gene dup/delete variant
<b>81201</b>	Apc gene full sequence	<b>81298</b>	Msh6 gene full seq
<b>81202</b>	Apc gene known fam variants	<b>81299</b>	Msh6 gene known variants
<b>81203</b>	Apc gene dup/delet variants	<b>81300</b>	Msh6 gene dup/delete variant
<b>81205</b>	Bckdhd gene	<b>81301</b>	Microsatellite instability
<b>81206</b>	Bcr/abl1 gene major bp	<b>81302</b>	Mecp2 gene full seq
<b>81207</b>	Bcr/abl1 gene minor bp	<b>81303</b>	Mecp2 gene known variant
<b>81208</b>	Bcr/abl1 gene other bp	<b>81304</b>	Mecp2 gene dup/delet variant
<b>81209</b>	Blm gene	<b>81310</b>	Npm1 gene
<b>81210</b>	Braf gene	<b>81311</b>	Nras gene variants exon 2&3
<b>81211</b>	Brca1&2 seq & com dup/del	<b>81313</b>	Pca3/klk3 antigen
<b>81212</b>	Brca1&2 185&5385&6174 var	<b>81314</b>	Pdgfra gene
<b>81213</b>	Brca1&2 uncom dup/del var	<b>81315</b>	Pml/raralpha com breakpoints
<b>81214</b>	Brca1 full seq & com dup/del	<b>81316</b>	Pml/raralpha 1 breakpoint
<b>81215</b>	Brca1 gene known fam variant	<b>81317</b>	Pms2 gene full seq analysis
<b>81216</b>	Brca2 gene full sequence	<b>81318</b>	Pms2 known familial variants
<b>81217</b>	Brca2 gene known fam variant	<b>81319</b>	Pms2 gene dup/delet variants
<b>81218</b>	Cebpa gene full sequence	<b>81321</b>	Pten gene full sequence
<b>81219</b>	Calr gene com variants	<b>81322</b>	Pten gene known fam variant
<b>81220</b>	Cftr gene com variants	<b>81323</b>	Pten gene dup/delet variant
<b>81221</b>	Cftr gene known fam variants	<b>81324</b>	Pmp22 gene dup/delet
<b>81222</b>	Cftr gene dup/delet variants	<b>81325</b>	Pmp22 gene full sequence
<b>81223</b>	Cftr gene full sequence	<b>81326</b>	Pmp22 gene known fam variant
<b>81224</b>	Cftr gene intron poly t	<b>81327</b>	Sept9 methylation analysis



People. Trust. Results.

Since 1960

<b>81225</b>	Cyp2c19 gene com variants	<b>81328</b>	Slco1b1 gene com variants
<b>81226</b>	Cyp2d6 gene com variants	<b>81330</b>	Smpd1 gene common variants
<b>81227</b>	Cyp2c9 gene com variants	<b>81331</b>	Snrpn/ube3a gene
<b>81228</b>	Cytogen micrarray copy nmbr	<b>81332</b>	Serpina1 gene
<b>81229</b>	Cytogen m array copy no&snp	<b>81334</b>	Runx1 gene targeted seq alys
<b>81230</b>	Cyp3a4 gene common variants	<b>81335</b>	Tpmt gene com variants
<b>81231</b>	Cyp3a5 gene common variants	<b>81340</b>	Trb@ gene rearrange amplify
<b>81232</b>	Dpyd gene common variants	<b>81341</b>	Trb@ gene rearrange dirprobe
<b>81235</b>	Egfr gene com variants	<b>81342</b>	Trg gene rearrangement anal
<b>81238</b>	F9 full gene sequence	<b>81346</b>	Tyms gene com variants
<b>81240</b>	F2 gene	<b>81350</b>	Ugt1a1 gene
<b>81241</b>	F5 gene	<b>81355</b>	Vkorc1 gene
<b>81242</b>	Fancc gene	<b>81361</b>	Hbb gene com variants
<b>81243</b>	Fmr1 gene detection	<b>81362</b>	Hbb gene known fam variant
<b>81244</b>	Fmr1 gene characterization	<b>81363</b>	Hbb gene dup/del variants
<b>81245</b>	Flt3 gene	<b>81364</b>	Hbb full gene sequence
<b>81246</b>	Flt3 gene analysis	<b>81370</b>	Hla i & ii typing lr
<b>81247</b>	G6pd gene alys cmn variant	<b>81371</b>	Hla i & ii type verify lr
<b>81248</b>	G6pd known familial variant	<b>81372</b>	Hla i typing complete lr
<b>81249</b>	G6pd full gene sequence	<b>81373</b>	Hla i typing 1 locus lr
<b>81250</b>	G6pc gene	<b>81374</b>	Hla i typing 1 antigen lr
<b>81251</b>	Gba gene	<b>81375</b>	Hla ii typing ag equiv lr
<b>81252</b>	Gjb2 gene full sequence	<b>81376</b>	Hla ii typing 1 locus lr
<b>81253</b>	Gjb2 gene known fam variants	<b>81377</b>	Hla ii type 1 ag equiv lr
<b>81254</b>	Gjb6 gene com variants	<b>81378</b>	Hla i & ii typing hr
<b>81255</b>	Hexa gene	<b>81379</b>	Hla i typing complete hr
<b>81256</b>	Hfe gene	<b>81380</b>	Hla i typing 1 locus hr
<b>81257</b>	Hba1/hba2 gene	<b>81381</b>	Hla i typing 1 allele hr
<b>81258</b>	Hba1/hba2 gene fam vrnt	<b>81382</b>	Hla ii typing 1 loc hr
<b>81259</b>	Hba1/hba2 full gene sequence	<b>81383</b>	Hla ii typing 1 allele hr
<b>81260</b>	Ikbkap gene	<b>81400</b>	Mopath procedure level 1
<b>81261</b>	Igh gene rearrange amp meth	<b>81401</b>	Mopath procedure level 2
<b>81262</b>	Igh gene rearrang dir probe	<b>81402</b>	Mopath procedure level 3
<b>81263</b>	Igh vari regional mutation	<b>81403</b>	Mopath procedure level 4
<b>81264</b>	Igk rearrangeabn clonal pop	<b>81404</b>	Mopath procedure level 5
<b>81265</b>	Str markers specimen anal	<b>81405</b>	Mopath procedure level 6
<b>81266</b>	Str markers spec anal addl	<b>81406</b>	Mopath procedure level 7
<b>81267</b>	Chimerism anal no cell selec	<b>81407</b>	Mopath procedure level 8
<b>81268</b>	Chimerism anal w/cell select	<b>81408</b>	Mopath procedure level 9
<b>81269</b>	Hba1/hba2 gene dup/del vrnts	<b>81479</b>	Unlisted molecular pathology

Please contact your APS Practice Manager with any questions you may have regarding this correspondence.